Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial

Novo Nordisk's (NOVOb.CO) Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed results from a late-stage trial presented on Friday.